Design, synthesis and biological evaluation of pyrimidine derivatives as novel CDK2 inhibitors that induce apoptosis and cell cycle arrest in breast cancer cells.

Cyclin-dependent kinase 2 (CDK2) plays a key role in eukaryotic cell cycle progression which could facilitate the transition from G1 to S phase. The dysregulation of CDK2 is closely related to many cancers. CDK2 is utilized as one of the most studied kinase targets in oncology. In this article, 24 benzamide derivatives were designed, synthesized and investigated for the inhibition activity against CDK2. Our results revealed that the compound 25 is a potent CDK2 inhibitor exhibiting a broad spectrum anti-proliferative activity against several human breast cancer cells. Additionally, compound 25 could block cell cycle at G0 or G1 and induce significant apoptosis in MDA-MB-468 cells. These findings highlight a rationale for further development of CDK2 inhibitors to treat human breast cancer.

[1]  L. Ouyang,et al.  Molecular Dynamics Simulation of Tryptophan Hydroxylase-1: Binding Modes and Free Energy Analysis to Phenylalanine Derivative Inhibitors , 2013, International journal of molecular sciences.

[2]  S. Lim,et al.  Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells. , 2006, The Journal of nutritional biochemistry.

[3]  Charles L. Brooks,et al.  Detailed analysis of grid‐based molecular docking: A case study of CDOCKER—A CHARMm‐based MD docking algorithm , 2003, J. Comput. Chem..

[4]  C. Deane,et al.  Type II Inhibitors Targeting CDK2. , 2015, ACS chemical biology.

[5]  A. Isacchi,et al.  Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. , 2009, Journal of medicinal chemistry.

[6]  A. Jemal,et al.  Breast cancer statistics, 2015: Convergence of incidence rates between black and white women , 2016, CA: a cancer journal for clinicians.

[7]  J. Maller,et al.  A Centrosomal Localization Signal in Cyclin E Required for Cdk2-Independent S Phase Entry , 2004, Science.

[8]  S. Okret,et al.  p57Kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells. , 1999, Molecular endocrinology.

[9]  Agnieszka K. Witkiewicz,et al.  The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.

[10]  A. Giordano,et al.  RB and cell cycle progression , 2006, Oncogene.

[11]  D. A. Ibrahim,et al.  Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors. , 2011, European journal of medicinal chemistry.

[12]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[13]  M. Noble,et al.  Identification and Characterization of an Irreversible Inhibitor of CDK2 , 2015, Chemistry & biology.

[14]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[15]  A. Giordano,et al.  Anticancer therapeutic strategies based on CDK inhibitors. , 2013, Current pharmaceutical design.

[16]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[17]  David M. Glover,et al.  Polo-like kinases: conservation and divergence in their functions and regulation , 2009, Nature Reviews Molecular Cell Biology.

[18]  L Meijer,et al.  Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. , 1997, European journal of biochemistry.

[19]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[20]  S. Zick,et al.  Clinical practice guidelines on the evidence‐based use of integrative therapies during and after breast cancer treatment , 2017, CA: a cancer journal for clinicians.

[21]  C. Frémaux,et al.  Capillary microfluidic electrophoretic mobility shift assays: application to enzymatic assays in drug discovery , 2010, Expert opinion on drug discovery.

[22]  Sabrina L. Spencer,et al.  The Proliferation-Quiescence Decision Is Controlled by a Bifurcation in CDK2 Activity at Mitotic Exit , 2013, Cell.

[23]  H. Chae,et al.  Deregulation of Cdk2 causes Bim-mediated apoptosis in p53-deficient tumors following actin damage , 2008, Oncogene.

[24]  Anna Vulpetti,et al.  3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. , 2004, Journal of medicinal chemistry.

[25]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  E. Lees,et al.  Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor , 2010, Molecular Cancer Therapeutics.

[27]  Diaa A Ibrahim,et al.  Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors. , 2010, European journal of medicinal chemistry.

[28]  P. Tosco,et al.  6-Cyclohexylmethoxy-5-(cyano-NNO-azoxy)pyrimidine-4-amine: a new scaffold endowed with potent CDK2 inhibitory activity. , 2013, European journal of medicinal chemistry.